Company Quick10K Filing
Live Current Media
10-Q 2020-03-31 Filed 2020-05-15
10-K 2019-12-31 Filed 2020-03-31
10-Q 2019-09-30 Filed 2019-11-14
10-Q 2019-06-30 Filed 2019-08-14
10-Q 2019-03-31 Filed 2019-05-15
10-K 2018-12-31 Filed 2019-04-01
10-Q 2018-09-30 Filed 2018-11-14
10-Q 2018-06-30 Filed 2018-08-14
10-Q 2018-03-31 Filed 2018-05-16
10-Q 2010-09-30 Filed 2010-11-15
10-Q 2010-06-30 Filed 2010-08-16
10-Q 2010-03-31 Filed 2010-05-14
10-K 2009-12-31 Filed 2010-03-29
8-K 2020-01-29 Enter Agreement, Exhibits
8-K 2019-03-21 Enter Agreement, Exhibits
8-K 2018-12-07 Enter Agreement, Other Events, Exhibits
8-K 2018-11-28 Officers, Other Events
8-K 2018-09-10 Enter Agreement, Exhibits

Live Current Media Financials

LIVC Metrics, Comps, Filings

Quarterly | Annual

Business

Live Current Media, Inc. (the "Company") was incorporated under the laws of the State of Nevada on October 10, 1995. The Company has an authorized capital of 500,000,000 shares of common stock with 34,837,625 shares currently issued and outstanding.

The Company operates its business through its wholly owned subsidiary, Domain Holdings Inc., originally formed under the laws of British Columbia, Canada on July 4, 1994 and re-domiciled to Alberta, Canada on April 14, 1999 ("DHI"). The Company is also the majority shareholder of Perfume, Inc. (95% ownership), formed under the laws of the State of Delaware on March 13, 2008. Perfume, Inc. is currently dormant and does not carry on an active business. References herein to the Company include DHI and Perfume, Inc. (collectively, the "Subsidiaries") unless otherwise stated.

On March 21, 2019, the Company executed a distribution agreement (the "Distribution Agreement") with Cell MedX Corp. ("Cell MedX" or the "Device Manufacturer"), pursuant to which Cell MedX granted to the Company exclusive worldwide rights to distribute the eBalance microcurrent device to households and individual users. Although the Company does not currently intend to abandon its domain name and website development business, the Company expects to devote the majority of its near-term business efforts to selling and distributing the eBalance device.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
OWC Pharmaceutical Research (OWCP) 0 0% -0.2 362% 1,773 1,467 100 0 6,420 6,420 -1,465
Headhunter Group (HHR)
United States Short Oil Fund (DNO) 0 -0% 0.0 0 0 -600 0 -1,856 -1,856 -0
Immune Therapeutics (IMUN) 0 0.0 -29,381% 8 13,479 0 0 -2,476 -2,475 -6
Juniper Industrial (JIH)
PositiveID Corp (PSID)
Live Current Media (LIVC) 0 2.8 -26% 418 108 0 0 -110 -109 -306
Sun Pacific Holding (SNPW) 0 30% -17.5 -20% 6,669 10,975 260 77 -1,301 -315 5,510
Digatrade Financial (DIGAF) 0 0% 527 778 0 0 0 0 0
Lingerie Fighting Championships (BOTY) 0 -49% 0.2 -8,950,200% 23 -11 90 -10 -2
New Century Resources (NCRE) 0 0.0 0 205 0 0 -18 -17 -0
Arete Industries (ARET)
Renewable Energy Acquisition (REAC) 0 0.0 2,353,600% 0 0 -24 -22 -0
Sundial Growers (SNDL)
Energy Transfer Operating (ETP) 0 27% 5.8 4% 95,247,000 59,636,000 40,493,000 10,886,000 3,786,000 8,016,000 46,523,000
Blue Line Protection Group (BLPG) 0 40% 0.0 -189% 1,661 5,917 3,017 1,201 -3,138 -2,534 -19
ABCO Energy (ABCE) 0 38% 0.1 -173% 411 1,359 1,627 622 -713 -502 -28
Guided Therapeutics (GTHP) 0 332% 0.1 1,462% 404 16,413 28 93 5,908 6,835 439
Endonovo Therapeutics (ENDV) 0 73% -0.8 -301% 3,414 19,980 204 150 -10,268 -9,617 7,448
Dominovas Energy (DNRG)

Balance Sheet ($'000)2018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash929776458389324372306
Accounts Receivable000000
Inventory
PP&E
Assets1,2261,049959523444485418
Accounts Payable21611995861229090
Long-Term Debt
Liabilities233137112103140107108
Stockholders' Equity993913846420304377311
Income Statement ($'000)2018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue
Cost of Revenue
Gross Profit
R&D
SG&A494760292823
Tax000000
Net Income-85-80-66-11673-67
Cash Flow ($'000)2018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-27-154-136-65-99-66
Cash Investing00
Cash Financing